Actuate Therapeutics receives Nasdaq bid price deficiency notice; 180 days to comply
Actuate Therapeutics received a Nasdaq notice on October 28, 2026, stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027 to regain compliance, and the stock continues to trade on The Nasdaq Global Market as ACTU for now. If it does not regain compliance, the stock could become subject to delisting, which matters to shareholders.
Key points
- Nasdaq notice received October 28, 2026 under Listing Rule 5450(a)(1)
- Compliance deadline is April 26, 2027; stock must close at or above $1.00 for at least 10 consecutive business days
- Separate July 15, 2026 notice on minimum market value of listed securities; regain compliance by January 11, 2027
- A second 180-day period may be available if the company moves its listing to the Nasdaq Capital Market
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.